what's trending

5 most popular innovation stories in Houston this week

Halliburton introduced its startup incubator, virtual events you can't miss, highlights from the Greater Houston Partnership's report, and more top news from the week. Shobeir Ansari/Getty Images

Editor's note: From a new energy tech incubator and innovators to know to the golden age of software startups and virtual events not to miss, check out the top stories in Houston innovation from this week.

3 Houston innovators to know this week

This week's Houston innovators to know includes Sola Lawal of Nuro, Jose Diaz-Gomez of CHI St. Luke's Health, and Kimberly Baker of UT School of Public Health. Courtesy photos

A key attribute of innovators and inventors is the ability to look forward — to see the need for their innovation and the difference it will make. Each of this week's innovators to know have that skill, whether it's predicting the rise of autonomous vehicles or seeing the future of health care. Continue reading.

Houston oil and gas giant premieres new startup incubator and names first participant

Houston-based oil field service company, Halliburton, has introduced its new startup incubator. Getty Images

Not intending to be left out of the energy transition, a Houston-based, multinational oil and gas services company has announced its new incubator for startups to advance cleaner, affordable energy.

Halliburton Company has introduced Halliburton Labs this week and named Houston-based Nanotech Inc., which uses nanotechnology for thermal insulation and fireproofing, as its first participant. Nanotech — along with future entrepreneurs and academics — will have access to the Halliburton facilities, the company's experts, and its network.

"Halliburton Labs reflects our commitment to the science and continued evolution of sustainable, reliable energy," says Jeff Miller, chairman, president, and CEO at Halliburton, in a news release. "We firmly believe that oil and gas will remain an affordable and reliable energy resource for decades to come. At the same time, we recognize the importance of developing alternative energy sources. We are excited to help advance solutions that have the potential for a long term, meaningful impact and that align well with our sustainability objectives." Continue reading.

10+ can't-miss virtual business and innovation events in Houston for August

Log on to one of these informative online events happening throughout the rest of the month. Getty Images

Another month, another roundup of events Houston innovators should attend — and yes, they are still all virtual. From Houston Exponential launching its new virtual database and networking platform to informative workshops and panels, here's what you need to attend this month. Continue reading.

5 innovation-focused takeaways from the Greater Houston Partnership's annual report

The Greater Houston Partnership has released its 2020 Houston Facts — here's what you need to know. Getty Images

In an annual economic report from the Greater Houston Partnership, researchers and data scientists outlined the city's economy by the numbers, and Houston's industries such as technology, health care, energy, and more were all represented. The 2020 Houston Facts was released in an virtual event hosted by GHP and its team of data specialists. Here's what you need to know from the event and the report. Continue reading.

Houston investor: Is this the golden age for B2B software?

This Houston venture capital leader is looking at how 2020 — for all its disappointments — might be a great year for B2B software-as-a-service companies. Getty Images

B2B software as a service, or SaaS, founders entered 2020 riding a wave of the longest economic expansion in United States history. Valuations increased to new highs, funding rounds continued getting larger at each stage, and forecasts went up and to the right fast. But then, March hit.

Quickly and seemingly out of nowhere, headlines became dominated by apocalyptic predictions of death, record levels of unemployment, shocking economic forecasts of GDP contraction, historic mass layoffs and furloughs, and unprecedented multi-trillion dollar economic stimulus packages. For founders every instinct began screaming to cut costs and hunker down.

But should B2B SaaS founders cut their organizations right now? Through analyzing a few key events and looking to the evidence in the market today, founders can develop a strategy for growing during this crisis. Not only is growth cheaper for most B2B SaaS against the backdrop of economic meltdown, but with the majority following a hunker-down instinct, a growing B2B SaaS firm will compare very favorably against a landscape of stale and stagnant competitors. Continue reading.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News